Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 168828-84-0 in 2025

Understanding CAS No. 168828-84-0 – A Key Docetaxel Intermediate

CAS No. 168828-84-0 is a critical intermediate in the semi-synthesis of Docetaxel, an important chemotherapy agent widely used to treat cancers such as breast, lung, prostate, and ovarian. This compound typically represents a protected and esterified side-chain intermediate, essential for achieving the correct chemical structure and therapeutic function of the final active pharmaceutical ingredient (API).

The precise stereochemistry and purity of this intermediate are crucial, as they directly affect the bioactivity, safety, and efficacy of the final Docetaxel product.

Importance of CAS No. 168828-84-0 in Pharmaceutical Manufacturing

Advanced Intermediate for Oncology APIs

This compound plays a vital role in forming the side chain of Docetaxel through a selective coupling process.

High Purity and Defined Stereochemistry

Only the (2R,3S)-isomer is used, requiring controlled synthesis methods and stringent purification.

Essential in Semi-Synthetic Pathways

Derived from 10-Deacetylbaccatin III, this intermediate is often the penultimate or final step before full Docetaxel synthesis.

Used by Global API Manufacturers and CDMOs

It is highly valued by companies looking to accelerate time-to-market for injectable oncology drugs.

Subject to GMP and Regulatory Compliance

Given its role in oncology drug development, manufacturers must adhere to ICH Q7, FDA, and EMA regulations for its production.

Top 10 Manufacturers of CAS No. 168828-84-0

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza offers late-stage cytotoxic intermediates, including protected Docetaxel side chains like CAS 168828-84-0, under full GMP.

• Specialty: High-containment facilities and oncology-focused synthesis.

2. Bachem AG

• Location: Bubendorf, Switzerland

• Overview: Bachem produces custom chiral intermediates for oncology APIs, with exacting control over stereoisomers and functional groups.

• Specialty: Amino acid derivatives and high-purity protected compounds.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine supplies CAS 168828-84-0 at commercial scale, with strong export capabilities, batch-to-batch consistency, and regulatory support.

• Specialty: Advanced oncology intermediates at competitive prices for global markets.

4. Dipharma Francis S.r.l.

• Location: Milan, Italy

• Overview: Dipharma offers semi-synthetic taxane intermediates and develops high-purity side-chain compounds for injectable APIs.

• Specialty: GMP production and chiral intermediate development.

5. Sterling Pharma Solutions

• Location: Newcastle, United Kingdom

• Overview: Sterling specializes in cytotoxic and highly potent API intermediates, with facilities designed for safe, contained manufacturing.

• Specialty: Custom synthesis of Docetaxel-related compounds and regulatory support.

6. CordenPharma

• Location: Plankstadt, Germany

• Overview: CordenPharma offers integrated support from intermediate to final API, especially for cancer drug components.

• Specialty: Full-route CDMO services for taxane APIs.

7. Almac Group

• Location: Craigavon, Northern Ireland

• Overview: Almac provides scale-up and GMP production of protected intermediates like CAS 168828-84-0 used in Docetaxel synthesis.

• Specialty: Flexible batch sizes, fast turnaround, and analytical support.

8. PharmaZell Group

• Location: Raubling, Germany

• Overview: PharmaZell manufactures intermediates for semisynthetic APIs and supports oncology portfolios globally.

• Specialty: Focus on European regulatory compliance and cytotoxic intermediates.

9. Enzymaster Life Sciences

• Location: Düsseldorf, Germany

• Overview: Enzymaster leverages biocatalysis to produce enantiomerically pure intermediates in a sustainable, green-chemistry fashion.

• Specialty: Chiral side-chain building blocks for oncology APIs.

10. Carbogen Amcis

• Location: Bubendorf, Switzerland

• Overview: Carbogen Amcis manufactures GMP-grade oncology intermediates, with strong expertise in taxane-related products.

• Specialty: High-potency manufacturing and regulatory-compliant supply.

Trends in the Pharmaceutical Intermediates Market

Rising Demand for Injectable Oncology Generics

Docetaxel is a widely prescribed injectable chemotherapy drug. The demand for intermediates like 168828-84-0 is growing alongside global generics.

Advanced Containment and Safety Standards

Companies are investing in containment and occupational safety due to the cytotoxic nature of taxane intermediates.

Emphasis on Enantiomeric Purity

Regulatory authorities demand accurate stereochemistry, making chiral synthesis and resolution technologies a core focus.

Outsourcing and CDMO Growth

Pharma companies are increasingly outsourcing intermediate production to experienced CDMOs to reduce cost and time-to-market.

Green Chemistry Integration

Biocatalysis, solvent recovery, and waste minimization are gaining traction as sustainability becomes essential in pharma supply chains.

Conclusion

CAS No. 168828-84-0 plays a pivotal role in the synthesis of Docetaxel, a critical oncology drug. As demand for affordable and effective chemotherapy treatments rises, manufacturers such as Lonza, Eastfine, Sterling, and Dipharma are delivering high-quality, GMP-compliant intermediates that meet the stringent requirements of global pharmaceutical companies.

This intermediate is an essential building block in the cancer treatment supply chain, enabling the production of life-saving therapies worldwide.